Manuel Carrasco

Manuel Carrasco

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 January 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MBMichael Buschmann
Michael Buschmann
MCManuel Carrasco
Manuel Carrasco
SASuman Alishetty
Suman Alishetty
MPMikell Paige
Mikell Paige
MAMohamad-Gabriel Alameh
Mohamad-Gabriel Alameh
DWDrew Weissman
Drew Weissman
The recent success of mRNA vaccines in SARS-CoV-2 clinical trials is in part due to the development of lipid nanoparticle delivery systems that not only efficiently express the mRNA-encoded immunogen after intramuscular injection, but also play roles as adjuvants and in vaccine reactogenicity. We present an overview of mRNA delivery systems and then focus on the lipid nanoparticles used in the current SARS-CoV-2 vaccine clinical trials. The review concludes with an analysis of the determinants of the performance of lipid nanoparticles in mRNA vaccines.

10 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DBDominique L. Brooks
Dominique L. Brooks
MCManuel Carrasco
Manuel Carrasco
PQPing Qu
Ping Qu
WPWilliam H. Peranteau
William H. Peranteau
RARebecca C. Ahrens-Nicklas
Rebecca C. Ahrens-Nicklas
XWXiao Wang
Xiao Wang
Phenylketonuria (PKU), an autosomal recessive disorder caused by pathogenic variants in the phenylalanine hydroxylase (PAH) gene, results in the accumulation of blood phenylalanine (Phe) to neurotoxic levels. Current dietary and medical treatments are chronic and reduce, rather than normalize, blood Phe levels. Among the most frequently occurring PAH variants in PKU patients is the P281L (c.842C>T) variant. Using a CRISPR prime-edited hepatocyte cell line and a humanized PKU mouse model, we demonstrate efficient in vitro and in vivo correction of the P281L variant with adenine base editing. With the delivery of ABE8.8 mRNA and either of two guide RNAs in vivo using lipid nanoparticles (LNPs) in humanized PKU mice, we observe complete and durable normalization of blood Phe levels within 48 h of treatment, resulting from corrective PAH editing in the liver. These studies nominate a drug candidate for further development as a definitive treatment for a subset of PKU patients.